Zaynich (WCK 5222)
cUTI, HABP/VABP caused by MDR Gram-negative bacteria
NDA FiledNDA/MAA Submitted to CDSCO, US FDA, EU EMA
Key Facts
Indication
cUTI, HABP/VABP caused by MDR Gram-negative bacteria
Phase
NDA Filed
Status
NDA/MAA Submitted to CDSCO, US FDA, EU EMA
Company
About Wockhardt
Wockhardt's mission is to address unmet medical needs through research, with a strategic pivot towards combating the global crisis of antimicrobial resistance (AMR). Its key achievement is the development of a late-stage pipeline of novel antibiotic combinations, most notably Zaynich (WCK 5222), which has filed for marketing authorization in India, the US, and EU after a successful global Phase III trial. The company's strategy leverages its deep expertise in complex chemistry and anti-infective R&D to develop first-in-class therapies, while maintaining a foundation of diversified pharmaceutical businesses and hospital services to support its innovative endeavors.
View full company profile